Immediate-early expression of a recombinant antigen by modified vaccinia virus Ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses

Journal of Virology

Volumn 84, Issue 17, 2010, Pages 8743-8752

  Baur, Karen ^a   Brinkmann, Kay ^a   Schweneker, Marc ^a   Pätzold, Juliane ^a   Meisinger Henschel, Christine ^a   Hermann, Judith ^a   Steigerwald, Robin ^a   Chaplin, Paul ^a   Suter, Mark ^a,b   Hausmann, Jürgen ^a  

^a Bavarian Nordic GmbH   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; OVALBUMIN; RECOMBINANT ANTIGEN; T LYMPHOCYTE ANTIGEN; VIRUS VECTOR; CD8 ANTIGEN; HYBRID PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MEMORY T LYMPHOCYTE; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; CHEMISTRY; CHICK EMBRYO; GENE EXPRESSION; GENE VECTOR; GENETICS; HAMSTER; IMMEDIATE EARLY GENE; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; VACCINIA; VACCINIA VIRUS; VIROLOGY;

MUS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD8; ANTIGENS, VIRAL; BASE SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; CHICK EMBRYO; CRICETINAE; FEMALE; GENE EXPRESSION; GENES, IMMEDIATE-EARLY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; OVALBUMIN; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; VACCINIA; VACCINIA VIRUS; VIRAL VACCINES;

EID: 77956628455     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00604-10     Document Type: Article

References (54)

1. Alcami, A., J. A. Symons, P. D. Collins, T. J. Williams, and G. L. Smith. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-633.
2. Anderson, R. J., C. M. Hannan, S. C. Gilbert, S. M. Laidlaw, E. G. Sheu, S. Korten, R. Sinden, G. A. Butcher, M. A. Skinner, and A. V. Hill. 2004. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J. Immunol. 172:3094-3100.
3. Assarsson, E., J. A. Greenbaum, M. Sundstrom, L. Schaffer, J. A. Hammond, V. Pasquetto, C. Oseroff, R. C. Hendrickson, E. J. Lefkowitz, D. C. Tscharke, J. Sidney, H. M. Grey, S. R. Head, B. Peters, and A. Sette. 2008. Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc. Natl. Acad. Sci. U. S. A. 105:2140-2145.
4. Ball, L. A. 1987. High-frequency homologous recombination in vaccinia virus DNA. J. Virol. 61:1788-1795.
5. Blattman, J. N., D. J. Sourdive, K. Murali-Krishna, R. Ahmed, and J. D. Altman. 2000. Evolution of the T cell repertoire during primary, memory, and recall responses to viral infection. J. Immunol. 165:6081-6090.
6. Bronte, V., M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. U. S. A. 94:3183-3188.
7. Broyles, S. S. 2003. Vaccinia virus transcription. J. Gen. Virol. 84:2293-2303.
8. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, and M. N. Robertson. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
9. Busch, D. H., I. Pilip, and E. G. Pamer. 1998. Evolution of a complex T cell receptor repertoire during primary and recall bacterial infection. J. Exp. Med. 188:61-70.
10. Carroll, M. W., and B. Moss. 1997. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
11. Cavallo, F., R. Offringa, S. H. van der Burg, G. Forni, and C. J. Melief. 2006. Vaccination for treatment and prevention of cancer in animal models. Adv. Immunol. 90:175-213.
12. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23:1094-1097.
13. Cochran, M. A., C. Puckett, and B. Moss. 1985. In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J. Virol. 54:30-37.
14. Cooney, E. L., A. C. Collier, P. D. Greenberg, R. W. Coombs, J. Zarling, D. E. Arditti, M. C. Hoffman, S. L. Hu, and L. Corey. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567-572.
15. Cottingham, M. G., R. F. Andersen, A. J. Spencer, S. Saurya, J. Furze, A. V. Hill, and S. C. Gilbert. 2008. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3:e1638.
16. Coupar, B. E., M. E. Andrew, G. W. Both, and D. B. Boyle. 1986. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur. J. Immunol. 16:1479-1487.
17. Davison, A. J., and B. Moss. 1989. Structure of vaccinia virus early promoters. J. Mol. Biol. 210:749-769.
18. Drexler, I., K. Heller, B. Wahren, V. Erfle, and G. Sutter. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79:347-352.
19. Emens, L. A. 2006. Roadmap to a better therapeutic tumor vaccine. Int. Rev. Immunol. 25:415-443.
20. Funahashi, S., S. Itamura, H. Iinuma, K. Nerome, M. Sugimoto, and H. Shida. 1991. Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses. J. Virol. 65:5584-5588.
21. Funahashi, S., T. Sato, and H. Shida. 1988. Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus. J. Gen. Virol. 69:35-47.
22. Gammon, D. B., and D. H. Evans. 2009. The 3′-to-5′ exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J. Virol. 83:4236-4250.
23. Gilbert, S. C., J. Schneider, C. M. Hannan, J. T. Hu, M. Plebanski, R. Sinden, and A. V. Hill. 2002. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20: 1039-1045.
24. Gomez, C. E., J. L. Najera, E. P. Jimenez, V. Jimenez, R. Wagner, M. Graf, M. J. Frachette, P. Liljestrom, G. Pantaleo, and M. Esteban. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25:2863-2885.
25. Ha, S. J., E. E. West, K. Araki, K. A. Smith, and R. Ahmed. 2008. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol. Rev. 223:317-333.
26. Hill, A. V., A. Reyes-Sandoval, G. O'Hara, K. Ewer, A. Lawrie, A. Goodman, A. Nicosia, A. Folgori, S. Colloca, R. Cortese, S. C. Gilbert, and S. J. Draper. 2010. Prime-boost vectored malaria vaccines: progress and prospects. Hum. Vaccin. 6:78-83.
27. Jin, N. Y., S. Funahashi, and H. Shida. 1994. Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression. Arch. Virol. 138:315-330.
28. Kastenmuller, W., G. Gasteiger, J. H. Gronau, R. Baier, R. Ljapoci, D. H. Busch, and I. Drexler. 2007. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J. Exp. Med. 204: 2187-2198.
29. Kennedy, J. S., and R. N. Greenberg. 2009. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev. Vaccines 8:13-24.
30. Kündig, T. M., C. P. Kalberer, H. Hengartner, and R. M. Zinkernagel. 1993. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11:1154-1158.
31. Liu, J., L. S. Wyatt, R. R. Amara, B. Moss, and H. L. Robinson. 2006. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine 24:3332-3339.
32. Liu, X., M. Kremer, and S. S. Broyles. 2004. A natural vaccinia virus promoter with exceptional capacity to direct protein synthesis. J. Virol. Methods 122:141-145.
33. Masopust, D. 2009. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of CD8 T-cell quantity, quality and location. J. Intern. Med. 265:125-137.
34. Matsumura, M., Y. Saito, M. R. Jackson, E. S. Song, and P. A. Peterson. 1992. In vitro peptide binding to soluble empty class I major histocompatibility complex molecules isolated from transfected Drosophila melanogaster cells. J. Biol. Chem. 267:23589-23595.
35. Mayr, A., V. Hochstein-Mintzel, and H. Stickl. 1975. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3:6-14.
36. Miller, J. D., R. G. van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, S. Germon, C. del Rio, M. J. Mulligan, S. I. Staprans, J. D. Altman, M. B. Feinberg, and R. Ahmed. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28:710-722.
37. Moss, B. 2007. Poxviridae: the viruses and their replication, p. 2905-2945. In D. M. Knipe et al. (ed.), Fields virology, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
38. Moutaftsi, M., B. Peters, V. Pasquetto, D. C. Tscharke, J. Sidney, H. H. Bui, H. Grey, and A. Sette. 2006. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat. Biotechnol. 24:817-819.
39. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8:177-187.
40. Patel, D. D., C. A. Ray, R. P. Drucker, and D. J. Pickup. 1988. A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 85:9431-9435.
41. Rooney, J. F., C. Wohlenberg, K. J. Cremer, B. Moss, and A. L. Notkins. 1988. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62:1530-1534.
42. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10:485-492.
43. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, K. J. Robson, C. M. Hannan, M. Becker, R. Sinden, G. L. Smith, and A. V. Hill. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397-402.
44. Staib, C., S. Kisling, V. Erfle, and G. Sutter. 2005. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J. Gen. Virol. 86:1997-2006.
45. Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schäfer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 99: 2386-2392.
46. Suter, M., C. Meisinger-Henschel, M. Tzatzaris, V. Hulsemann, S. Lukassen, N. H. Wulff, J. Hausmann, P. Howley, and P. Chaplin. 2009. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain. Vaccine 27:7442-7450.
47. Sutter, G., and C. Staib. 2003. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3:263-271.
48. Timm, A., C. Enzinger, E. Felder, and P. Chaplin. 2006. Genetic stability of recombinant MVA-BN. Vaccine 24:4618-4621.
49. Tscharke, D. C., G. Karupiah, J. Zhou, T. Palmore, K. R. Irvine, S. M. Haeryfar, S. Williams, J. Sidney, A. Sette, J. R. Bennink, and J. W. Yewdell. 2005. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J. Exp. Med. 201:95-104.
50. Vollmar, J., N. Arndtz, K. M. Eckl, T. Thomsen, B. Petzold, L. Mateo, B. Schlereth, A. Handley, L. King, V. Hülsemann, M. Tzatzaris, K. Merkl, N. Wulff, and P. Chaplin. 2006. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24: 2065-2070.
51. von Krempelhuber, A., J. Vollmar, R. Pokorny, P. Rapp, N. Wulff, B. Petzold, A. Handley, L. Mateo, H. Siersbol, H. Kollaritsch, and P. Chaplin. 2010. A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28:1209-1216.
52. Webster, D. P., S. Dunachie, J. M. Vuola, T. Berthoud, S. Keating, S. M. Laidlaw, S. J. McConkey, I. Poulton, L. Andrews, R. F. Andersen, P. Bejon, G. Butcher, R. Sinden, M. A. Skinner, S. C. Gilbert, and A. V. Hill. 2005. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. U. S. A. 102:4836-4841.
53. Wu, T. C. 2007. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur. J. Immunol. 37:310-314.
54. Wyatt, L. S., P. L. Earl, J. Vogt, L. A. Eller, D. Chandran, J. Liu, H. L. Robinson, and B. Moss. 2008. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26:486-493.